Idorsia notes potential $440.8M Asia licensing deal to extend cash runway amid slow Quviviq sales
Swiss biopharma Idorsia gave out few details Tuesday about a potential $440.8 million (400 million CHF) deal with an unnamed company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
